SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                    FORM 8-K


                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934


         Date of Report (date of earliest event reported): March 6, 2009


                               CEL-SCI CORPORATION
                          ------ --------------------
             (Exact name of Registrant as specified in its charter)


          Colorado                      0-11503                 84-0916344
--------------------------------------------------------------------------------
(State or other jurisdiction     (Commission File No.)        (IRS Employer
      of incorporation)                                     Identification No.)

                              8229 Boone Blvd. #802
                                Vienna, VA 22182
                -------------------------------------------------
          (Address of principal executive offices, including Zip Code)


       Registrant's telephone number, including area code: (703) 506-9460
                                                           --------------



                                       N/A
                 ---------------------------------------------
          (Former name or former address if changed since last report)


<PAGE>

Item 1.01  Entry Into a Material Definitive Agreement

     Effective  March 6,  2009  CEL-SCI  Corporation  entered  into a  licensing
agreement with Byron  Biopharma LLC ("Byron")  under which CEL-SCI granted Byron
an exclusive license to market and distribute CEL-SCI's cancer drug Multikine(R)
in the Republic of South Africa.  CEL-SCI has existing licensing  agreements for
Multikine with Teva Pharmaceuticals and Orient Europharma.

     Pursuant to the agreement  Byron will be responsible  for  registering  the
product in South Africa. Once Multikine has been approved for sale, CEL-SCI will
be responsible for  manufacturing  the product,  while Byron will be responsible
for sales in South Africa.  Revenues will be divided equally between CEL-SCI and
Byron.  To maintain  the license  Byron,  among  other  requirements,  must make
milestone  payments to CEL-SCI  totaling  $125,000 on or before  March 15, 2010.
Byron also agreed to purchase  shares of common stock and warrants  from CEL-SCI
for $750,000.





<PAGE>

                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


Date:  March 12, 2009

                                 CEL-SCI CORPORATION



                                 By:  /s/ Geert R. Kersten
                                     -----------------------------------------
                                      Geert R. Kersten, Chief Executive Officer
[{"type": "8-K", "sequence": "1", "filename": "form8kdefagree3-09.txt", "secsgml_size_bytes": 3023}]
{"company-data": {"conformed-name": "CEL SCI CORP", "cik": "0000725363", "assigned-sic": "2836", "irs-number": "840916344", "state-of-incorporation": "CO", "fiscal-year-end": "0930"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-11889", "film-number": "09674873"}, "business-address": {"street1": "8229 BOONE BLVD .", "street2": "SUITE 802", "city": "VIENNA", "state": "VA", "zip": "22182", "phone": "7035069460"}, "mail-address": {"street1": "8229 BOONE BLVD.", "street2": "SUITE 802", "city": "VIENNA", "state": "VA", "zip": "22182"}, "former-company": {"former-conformed-name": "INTERLEUKIN 2 INC", "date-changed": "19880317"}}
SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

         Date of Report (date of earliest event reported): March 6, 2009

                               CEL-SCI CORPORATION
                          ------ --------------------
             (Exact name of Registrant as specified in its charter)

          Colorado                      0-11503                 84-0916344
--------------------------------------------------------------------------------
(State or other jurisdiction     (Commission File No.)        (IRS Employer
      of incorporation)                                     Identification No.)

                              8229 Boone Blvd. #802
                                Vienna, VA 22182
                -------------------------------------------------
          (Address of principal executive offices, including Zip Code)

       Registrant's telephone number, including area code: (703) 506-9460
                                                           --------------

                                       N/A
                 ---------------------------------------------
          (Former name or former address if changed since last report)
Item 1.01  Entry Into a Material Definitive Agreement

     Effective  March 6,  2009  CEL-SCI  Corporation  entered  into a  licensing
agreement with Byron  Biopharma LLC ("Byron")  under which CEL-SCI granted Byron
an exclusive license to market and distribute CEL-SCI's cancer drug Multikine(R)
in the Republic of South Africa.  CEL-SCI has existing licensing  agreements for
Multikine with Teva Pharmaceuticals and Orient Europharma.

     Pursuant to the agreement  Byron will be responsible  for  registering  the
product in South Africa. Once Multikine has been approved for sale, CEL-SCI will
be responsible for  manufacturing  the product,  while Byron will be responsible
for sales in South Africa.  Revenues will be divided equally between CEL-SCI and
Byron.  To maintain  the license  Byron,  among  other  requirements,  must make
milestone  payments to CEL-SCI  totaling  $125,000 on or before  March 15, 2010.
Byron also agreed to purchase  shares of common stock and warrants  from CEL-SCI
for $750,000.
SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Date:  March 12, 2009

                                 CEL-SCI CORPORATION

                                 By:  /s/ Geert R. Kersten
                                     -----------------------------------------
                                      Geert R. Kersten, Chief Executive Officer